

Development of multi-specific fusion protein modulating multiple angiogenesis pathways for the treatment of retinal vascular diseases



OPHTHALMOLOGY	Candidate
Product Type	rProtein
Indication	wAMD, DME, DR
Target	VEGF-A, VEGF-B, PlGF, Ang-2
MoA(Mechanism of Action)	Multiple inhibition of VEGF receptor ligands and modulation of Tie2 pathway via ALTS-OP01 specific for VEGF-A, VEGF-B, PlGF, and Ang-2
Competitiveness	<ul style="list-style-type: none"> • Higher potency <i>in vitro</i> and <i>in vivo</i> compared to aflibercept and faricimab • High dose formulation enabling IVT injection up to 7.7 mg/eye • Longer duration compared to aflibercept and faricimab.
Development Stage	Candidate
Route of Administration	Intravitreal

Any unauthorized distribution or reproduction of this material is strictly prohibited.